Business
Trevi Therapeutics to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference
Fireside chat with management on February 25, 2026, at 9:20 a.m. ETNEW HAVEN, Conn., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced that Jennifer Good, President and Chie
About this update from Trevi Therapeutics, Inc.
[{"type":"image","alt":"Trevi Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Trevi Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":178,"url":"https://media.zenfs.com/en/globenewswire.com/c14a2e1b9a13526379b2ef57e4bfacf2"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/kycDft9JIG7MOq7uSFFDpg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTI0OTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/c14a2e1b9a13526379b2ef57e4bfacf2","width":300,"height":178}},"lazy":false},{"type":"text","content":"Fireside chat with management on February 25, 2026, at 9:20 a.m. ET","length":67,"tagName":"p"},{"type":"text","content":"NEW HAVEN, Conn., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced that Jennifer Good, President and Chief Executive Officer, and David Hastings, Chief Financial Officer, will participate in a fireside chat at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on Wednesday, February 25, at 9:20 a.m. ET. Held virtually from February 25-26, Ms. Good and Mr. Hastings will also participate in investor meetings with attendees of the event. This fireside chat and meetings will be available for conference attendees.","length":855,"tagName":"p"},{"type":"text","content":"About Trevi Therapeutics, Inc. Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine extended-release) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC). Haduvio is the first and only investigational therapy to show a statistically-significant reduction in cough frequency in clinical trials across both patients with IPF chronic cough and in patients with RCC. Haduvio acts on the cough reflex arc both centrally and peripherally as a kappa agonist and a mu antagonist (KAMA), targeting opioid receptors that play a key role in controlling chronic cough. Nalbuphine is not ...